Shares of Corvus Pharmaceuticals rose after its investigational drug soquelitinib showed positive results in an early-stage trial in atopic dermatitis patients. The stock surged 50% to $12.10 in ...

Amlitelimab is an investigational anti-OX40 ligand monoclonal antibody designed to normalize the overactive immune response in patients with atopic dermatitis.

Sanofi's amlitelimab confirms its potential in atopic dermatitisIn the SHORE phase 3 study, amlitelimab in combination with topical therapies met ...

Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...

If you’re a person of color, finding the right treatment for atopic dermatitis, a common form of eczema, can be challenging. Even though the disease is more prevalent in Black Americans than white ...

SILVERBERG: As a board-certified dermatologist in an academic referral center, I encounter a substantial caseload of patients with atopic dermatitis and other chronic inflammatory skin conditions.

Preclinical in vivo efficacy data in atopic dermatitis extend previous PoC in allergic asthma Positive opinion from the European Patent Office ...

Investing.com -- Corvus Pharmaceuticals (NASDAQ:CRVS) stock surged 48% Tuesday morning following the company’s announcement ...

In this video interview, Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at the Northwestern ...

Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being treated with topical steroids are concerned about side effectsNearly 8 in 10 ...

Experts discuss the importance of balancing effective symptom control with quality of life in managing chronic pediatric atopic dermatitis, emphasizing personalized treatment plans that address both ...

NEMLUVIO is the first authorized monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling ...